Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | POLA1 | P09884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407458 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL19141 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL4204017 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL719374 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL7408161 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL989611 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL9353850 | 1.00 | TSHR (0.64) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL642929 | 0.98 | TSHR (0.67) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL48697 | 0.93 | TSHR (0.75) | TSHRALDH1A1LMNATP53KAT2B | |
| SCHEMBL3502791 | 0.87 | TSHR (0.82) | TSHRALDH1A1LMNAKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | claimed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | claimed |
| EP-1841747-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK Corporation (KR) | 2007-10-10 | — | — | EP | claimed |
| WO-2006075888-A1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK CORPORATION (KR) | 2006-07-20 | — | — | WO | claimed |
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12522612-B2 | PDE4 inhibitors, pharmaceutical compositions, and therapeutic applications | BIOTHERYX INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MAN INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-12215068-B2 | Constrained lipids and methods of use thereof | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2025-02-04 | — | — | US | disclosed |
| EP-4452928-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| EP-4402121-A1 | ACYCLIC LIPIDS AND METHODS OF USE THEREOF | Renagade Therapeutics Management Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118317944-A | Acyclic lipids and methods of use thereof | 雷纳嘉德医疗管理公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-1993023039-A1 | SUBSTITUTED 4-AZA-5A-ANDROSTAN-ONES AS 5A-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023420-A1 | NEW 7β-SUBSTITUTED-4-AZA-5α-ANDROSTAN-3-ONES AS 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023038-A1 | 17-AMINO SUBSTITUTED 4-AZASTEROID 5α-REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1993-11-25 | — | — | WO | disclosed |
| US-5166390-A | Bactericides | ROHM AND HAAS COMPANY (US) | 1992-11-24 | — | — | US | disclosed |
| US-5135637-A | Eerrocene derivatives, surfactants containing same and process for producing organic thin films | IDEMITSU KOSAN CO., LTD. (JP) | 1992-08-04 | — | — | US | disclosed |
| US-5041582-A | Novel ferrocene derivatives, surfactants containing same and process for producing organic thin films | IDEMITSU KOSAN CO., LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | disclosed |
| EP-0394663-A1 | Novel ferrocene derivatives, surfactants containing same and process for producing organic thin films | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313525-A1 | CONSTRAINED LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | TSHR 2825/4885ALDH1A1 4876/4885LMNA 755/4885 |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | HDAC1, HDAC5, HDAC7 | TSHR 4146/4885ALDH1A1 424/4885LMNA 3307/4885 |
| US-12545636-B2 | Acyclic lipids and methods of use thereof | PLTP, LNPEP, PCTP | TSHR 1278/4885ALDH1A1 4885/4885LMNA 458/4885 |
| US-12215068-B2 | Constrained lipids and methods of use thereof | SGMS1, SGMS2, LNPEP | TSHR 2825/4885ALDH1A1 4876/4885LMNA 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.